. An ice shelf of the extent suggested by Jakobsson and colleagues' work is very different from the expansive sea ice that covers the Arctic Ocean today. Sea ice constantly opens and closes, providing gaps for light; this allows photosynthesis to occur and thus to fuel the vast Arctic marine ecosystem. Just as scientists contemplate the effect of more open water as Arctic sea ice is progressively reduced in response to climate change, an equally daunting task is to imagine how the ecosystem could function under the continual darkness and cover that the GAIS would have caused. A more limiting scenario for life could not be imagined, with the exception of the subglacial lakes that lie beneath the Antarctic ice sheet.
Equally important is the role that the GAIS must have had in regulating ocean chemistry while not greatly changing sea level. The implications of the changes in ocean chemistry for estimates of ancient sea levels can be appreciated by considering how climate scientists conventionally reconstruct sea-level oscillations. To reconstruct ancient glaciations largely lacking geological features that directly indicate shorelines, scientists have used the geochemical history of the ocean recorded in the shells of marine plankton called foraminifera. Glacial oceans are enriched in heavy-oxygen atoms ( 18 O), and so the change in chemistry over time -measured as the ratio of light-oxygen atoms to heavy oxygen in foraminifera shells -is used to gauge sea-level changes caused by the comings and goings of large ice sheets 10 . This method has been validated for the most recent glacial cycle, because direct measures of sea level are an exceedingly good match to estimates based on ice-sheet volume and changes in ocean chemistry 11 . But estimates for sea-level change during the penultimate glaciation have always been problematic, because the few direct shoreline records of sea level are higher than estimates based on the oxygenisotope record corresponding to that period 12 .
Jakobsson and co-workers' reconstructed GAIS seems to explain this mismatch, and reminds climate scientists that they should check their assumptions as they continue to account for glacial ice and its effects on sea level during the numerous glacial episodes of the past 2. 
AGEING

Out with the old
The selective elimination of cells that have adopted an irreversible, senescent state has now been shown to extend the lifespan of mice and to ameliorate some age-related disease processes. See Article p.184
J E S Ú S G I L & D O M I N I C J . W I T H E R S
T he ability to fight the ageing process has been a long-held human desire. Although this quest often seems to be driven by vanity, ageing is the major risk factor for many of the diseases that plague modern society. More than 50 years ago, it was suggested that ageing is linked to a state of arrested cell growth known as senescence 1 , but this link has remained unproven, and the molecular basis for organismal ageing has been elusive. In this issue, Baker et al. 2 (page 184) demonstrate that the removal of senescent cells does indeed delay ageing and increase healthy lifespan (healthspan).
Senescence is a cellular state in which cells permanently stop dividing. It is mediated by two signalling pathways -the p53 pathway and the p16 Ink4a -Rb pathway. Senescent cells secrete a complex cocktail of factors called the senescence-associated secretory phenotype (SASP), which includes matrix metallo proteinases (enzymes that break down the extra cellular matrix) and proinflammatory signalling molecules. Such cells have been shown to accumulate during ageing, and their presence has been associated with a broad range of diseases, including diabetes, kidney disease and many cancers 3 . The group that performed the current study previously showed that removing senescent cells from a mouse model of accelerated ageing delays the onset of several disease-related processes 4 . However, the relevance of these observations to the normal ageing process was unclear. Baker Baker and colleagues found that the elimination of p16
Ink4a -expressing cells increased lifespan, regardless of the sex or strain of mouse examined, and ameliorated a range of age-dependent, disease-related abnormalities, including kidney dysfunction and abnormalities in heart and fat tissue (Fig. 1) . The authors observed increased activity and exploratory behaviour and a decrease in the incidence of cataracts (although this improvement was strain-dependent). Senescent-cell removal also delayed the onset of cancer, without affecting the range of observed tumour types. Together, these findings suggest that the accumulation of p16
Ink4a
-expressing cells during normal ageing shortens healthspan.
The INK-ATTAC mouse is a powerful model with which to investigate the physiological relevance of senescence, but it is not without limitations. For instance, the model is assumed to selectively eliminate senescent cells -and although not all p16
Ink4a -expressing cells are necessarily senescent, the ATTAC transgene that produces the caspase seems to be expressed only in senescent cells. However, it could be that drug treatment kills only 'late senescence' cells 5 , which express high levels of p16 Ink4a and ATTAC, rather than triggering a more general elimination of senescence. Moreover, drug treatment does not kill some senescent cells, including immune cells called lymphocytes as well as liver and colon cells, which limits the reach of the model. An improved characterization of the cell types that are eliminated is needed to fully understand the basis of the extended healthspan of these animals.
Another caveat is that the inducible elimination of senescent cells requires twiceweekly, long-term injections into the abdomen. Males that were injected with a control solution rather than the drug typically had shorter lifespans than normal mice, perhaps because of this intensive treatment regime. More-sophisticated model animals, in which senescent cells can be ablated in different tissues at different times and without the need for repeated injections, would help to extend the current findings.
Although the ablation of senescent cells ameliorates some age-related defects, it has no effect on others, including declines in motor performance, muscle strength and memory. This could reflect limitations of the ATTAC model. However, it might also suggest that senescent cells are involved in the progression of only some diseases.
Why might eliminating just the few cells that are senescent have beneficial effects in a range of tissues? Baker and colleagues' analysis of the kidney might help to explain this observation and clarify why senescent cells can be so disruptive during ageing. A striking disease-associated change often arises in aged kidneys, in capillary networks called glomeruli. However, the authors observed senescence primarily in another cell type, the epithelial cells of the kidney tubules. This suggests that SASP components secreted by epithelial cells could be responsible for disease in the glomeruli.
A search for compounds that can selectively eliminate senescent cells is under way 6, 7 , and could be an important step in translating the findings of Baker and colleagues' study to combating diseases of ageing in humans. An alternative therapeutic approach could be to repress the SASP. Indeed, inhibition of JAK proteins, which mediate the actions of some cytokines (a type of signalling molecule), reduces the SASP and alleviates frailty in old mice 8 . Rapamycin, a drug that is used as an immuno suppressant in humans, also robustly extends mouse life span 9 and regulates the SASP 10, 11 . Thus, common therapeutic mechanisms acting on the SASP might underlie the beneficial effects of both rapamycin and senescent-cell ablation on lifespan and healthspan.
It is worth noting that senescence is a protective response that limits tissue scarring (fibrosis) and cancer. Cells that express senescence markers are also involved in wound healing. Interestingly, the current study suggests that, although ablating senescent cells impairs wound healing, in general it has limited negative effects, and the authors found no evidence for increased fibrosis or cancer development. Nonetheless, any future senescence-based therapies must take care to control for possible detrimental consequences. ■ 
Jesús Gil
PLASMA PHYSICS
Compact coupling for a two-stage accelerator
Injecting electrons that have been accelerated by a laser-powered plasma wave into a second plasma wave represents a two-step electron accelerator. With 100 such steps, collider applications become possible. See Letter p.190
B R I G I T T E C R O S
L aser-plasma acceleration is a means of accelerating electrons in a plasma -a fluid of positively and negatively charged particles -using electric fields that are 1,000 times stronger than those of conventional particle accelerators operating in a vacuum. However, despite major advances in the past few years, reliable laser-plasma accelerators have still not been built. On page 190 of this issue, Steinke et al. 1 describe a way in which the coupling of electron beams can be controlled with plasmas. The authors' achievement could lead to the development of laser-driven electron accelerators that can be scaled up to achieve energy gains on a par with those of today's particle accelerators. Such electron accelerators would fit on a tabletop, and could replace conventional machines at medical facilities, for instance.
Plasma waves -collective oscillations of electrons on a background of heavier, stationary ions -are intrinsic characteristics of plasmas. The oscillating electrons lead to a charge separation in the plasma wave that is associated with an electric field of up to several hundred gigavolts per metre. Plasma waves can be generated by the application of an intense, ultrashort laser pulse 2 ( Fig. 1) , which acts like a snow plough to expel electrons from the most intense regions of the plasma.
Depending on the laser intensity, plasma waves exist in either the quasilinear or the nonlinear regime (according to the wave equations that describe them). In the quasilinear case, plasma waves provide a periodic accelerating structure for injected particle beams
